Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CervoMed Inc.CRVO · Entity 7338 | Director · CEO & President · 10% owner | June 08, 2026 | June 10, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Med. Dev. Group & CMO | October 01, 2008 | October 02, 2008 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CervoMed Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2036-06-08 | IndirectBy Spouse | 8,150 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 8,150 · Balance 8,150 F1: Consists of an option to purchase shares of common stock granted to Sylvie Gregoire, PharmD., the Reporting Person's spouse and a non-employee director of the Issuer. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F2: The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Dr. Gregoire's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of an option to purchase shares of common stock granted to Sylvie Gregoire, PharmD., the Reporting Person's spouse and a non-employee director of the Issuer. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F2: The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Dr. Gregoire's continued service through the applicable vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date October 01, 2008 · Filed October 02, 2008
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 136,792 |
Ending reported balance
After 2008-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2008-10-01 · Exercise / conversion · Acquired 4,253 · Balance 141,045 Row 2 · 2008-10-01 · Sale · Disposed 4,253 · Balance 136,792 F1: Transaction for sales of common stock made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $32.65 (range $32.30 to $33.08). F3: Dr. Alam undertakes to provide (upon request by the SEC staff, the issuer or security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.63 · Expires 2008-12-09 | Direct | 12,761 |
Reported balance
After 2008-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2008-10-01 · Exercise / conversion · Disposed 4,253 · Balance 12,761 F4: Fully vested. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 5,140 |
Reported balance
Holding disclosure · report date 2008-10-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,140 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction for sales of common stock made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $32.65 (range $32.30 to $33.08).
F3: Dr. Alam undertakes to provide (upon request by the SEC staff, the issuer or security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 10, 2026 23:42 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 8,150 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001437749-26-020210 · rdgdoc.xml · derivative · entry 1 ALAM JOHN J · CIK 0001197014 · Director · CEO & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 8,150 Underlying: Common Stock · 8,150 shares Expires 2036-06-08 F1 · security: Consists of an option to purchase shares of common stock granted to Sylvie Gregoire, PharmD., the Reporting Person's spouse and a non-employee director of the Issuer. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F2 · derivative.exercise_date: The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Dr. Gregoire's continued service through the applicable vesting date. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 22:00 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001437749-26-004162 · rdgdoc.xml · derivative · entry 1 ALAM JOHN J · CIK 0001197014 · Director · CEO & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-02-11 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 12:45 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseCommon Stock | 10,793 | $8.46 | $91,308.78 |
DisclosureSEC source: 0001437749-25-035652 · rdgdoc.xml · nonDerivative · entry 2 ALAM JOHN J · CIK 0001197014 · Director · CEO & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Spouse's IRA Disclosed balance after: 12,500 F1 · shares: Shares purchased in open-market transactions. F4 · shares: Shares held by the Sylvie Gregoire Roth IRA. F5 · price: The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $8.38 to $8.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. F4 · balance_after: Shares held by the Sylvie Gregoire Roth IRA. F4 · ownership.nature: Shares held by the Sylvie Gregoire Roth IRA. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 12:45 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseCommon Stock | 10,807 | $8.46 | $91,427.22 |
DisclosureSEC source: 0001437749-25-035652 · rdgdoc.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · Director · CEO & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,484,078 F1 · shares: Shares purchased in open-market transactions. F2 · price: The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $8.39 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. F3 · balance_after: Includes (i) 1,471,578 shares held jointly by the Reporting Person and his spouse, Dr. Sylvie Gregoire, PharmD., a member of the Issuer's Board of Directors and (ii) 12,500 shares held by the John J. Alam Roth IRA. Read SEC document |
| November 14, 2025 Filed Nov 17, 2025 14:01 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseCommon Stock | 1,707 | $7.57 | $12,921.99 |
DisclosureSEC source: 0001437749-25-035309 · rdgdoc.xml · nonDerivative · entry 3 ALAM JOHN J · CIK 0001197014 · Director · CEO & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Spouse's IRA Disclosed balance after: 1,707 F1 · shares: Shares purchased in open-market transactions. F4 · shares: Includes 1,707 shares held by the Sylvie Gregoire Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.44 to $7.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. F4 · price: Includes 1,707 shares held by the Sylvie Gregoire Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.44 to $7.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. F4 · balance_after: Includes 1,707 shares held by the Sylvie Gregoire Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.44 to $7.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. F4 · ownership.nature: Includes 1,707 shares held by the Sylvie Gregoire Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.44 to $7.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. Read SEC document |
| November 14, 2025 Filed Nov 17, 2025 14:01 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseCommon Stock | 1,693 | $7.55 | $12,782.15 |
DisclosureSEC source: 0001437749-25-035309 · rdgdoc.xml · nonDerivative · entry 2 ALAM JOHN J · CIK 0001197014 · Director · CEO & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,473,271 F1 · shares: Shares purchased in open-market transactions. F3 · shares: Includes 1,693 shares held by the John J. Alam Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.41 to $7.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. F3 · price: Includes 1,693 shares held by the John J. Alam Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.41 to $7.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. F2 · balance_after: Includes 1,471,578 shares held jointly by the Reporting Person and his spouse, Dr. Sylvie Gregoire, PharmD., a member of the Issuer's Board of Directors. F3 · balance_after: Includes 1,693 shares held by the John J. Alam Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.41 to $7.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 14:01 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseCommon Stock | 4,447 | $7.51 | $33,396.97 |
DisclosureSEC source: 0001437749-25-035309 · rdgdoc.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · Director · CEO & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,471,578 F1 · shares: Shares purchased in open-market transactions. F2 · balance_after: Includes 1,471,578 shares held jointly by the Reporting Person and his spouse, Dr. Sylvie Gregoire, PharmD., a member of the Issuer's Board of Directors. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 13:52 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseCommon Stock | 5,553 | $7.35 | $40,814.55 |
DisclosureSEC source: 0001437749-25-034638 · rdgdoc.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · Director · CEO & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,467,131 F1 · shares: Shares purchased in open-market transactions. F2 · balance_after: Shares held jointly by the Reporting Person and his spouse, Dr. Sylvie Gregoire, PharmD., a member of the Issuer's Board of Directors. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:05 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 8,100 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001437749-25-021275 · rdgdoc.xml · derivative · entry 1 ALAM JOHN J · CIK 0001197014 · Director · CEO & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 8,100 Underlying: Common Stock · 8,100 shares Expires 2035-06-23 F1 · security: Consists of an option to purchase shares of common stock granted to Sylvie Gregoire, PharmD., the Reporting Person's spouse and a non-employee director of the Issuer. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F2 · derivative.exercise_date: The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2025, subject to the Dr. Gregoire's continued service through the applicable vesting date. Read SEC document |
| February 04, 2025 Filed Feb 14, 2025 23:00 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001437749-25-004071 · rdgdoc.xml · derivative · entry 1 ALAM JOHN J · CIK 0001197014 · Director · CEO & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-02-04 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2025. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 22:28 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 5,750 | $0.00 Strike: $19.01 | $0.00 |
DisclosureSEC source: 0001437749-24-020414 · rdgdoc.xml · derivative · entry 1 ALAM JOHN J · CIK 0001197014 · Director · CEO & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 5,750 Underlying: Common Stock · 5,750 shares Expires 2034-06-14 F1 · security: Consists of an option to purchase shares of common stock granted to Sylvie Gregoire, PharmD., the Reporting Person's spouse and a non-employee director of the Issuer. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F2 · derivative.exercise_date: The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2024, subject to the Dr. Gregoire's continued service through the applicable vesting date. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 23:47 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 35,500 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001437749-24-002349 · rdgdoc.xml · derivative · entry 1 ALAM JOHN J · CIK 0001197014 · Director · CEO & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,500 Underlying: Common Stock · 35,500 shares Expires 2034-01-26 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing January 31, 2024. Read SEC document |
| November 09, 2023 Filed Nov 10, 2023 00:41 UTC | CervoMed Inc. CRVO · Entity 7338 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-031329 · rdgdoc.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · Director · CEO & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 729,539 F1 · balance_after: Represents one or more bona fide gifts of the Issuer's Common Stock by the Reporting Person (such shares, the "Gift Shares") to certain friends and/or family members who are not immediate family members sharing the same household. In accordance with the terms of the lock-up agreement, dated March 30, 2023, by and between the Reporting Person and the Issuer (the "Lock-Up Agreement"), in connection with the transfer(s) of the Gift Shares, each transferee will be subject to an agreement pursuant to which the transferee agrees not to further transfer the Gift Shares prior to August 16, 2024, subject to certain exceptions, on terms substantially similar to those set forth in the Lock-Up Agreement. Following the transaction, the Reporting Person has neither investment control over nor a pecuniary interest in the Gift Shares. Read SEC document |
| September 15, 2023 Filed Sep 15, 2023 22:54 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 6,450 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001437749-23-026076 · rdgdoc.xml · derivative · entry 2 ALAM JOHN J · CIK 0001197014 · Director · CEO & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 6,450 Underlying: Common Stock · 6,450 shares Expires 2033-09-15 F2 · security: Consists of an option to purchase shares of common stock granted to Sylvie Gregoire, Pharm.D., the Reporting Person's spouse and the Chair of the Board of the Issuer. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing September 30, 2023. Read SEC document |
| September 15, 2023 Filed Sep 15, 2023 22:54 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 35,500 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001437749-23-026076 · rdgdoc.xml · derivative · entry 1 ALAM JOHN J · CIK 0001197014 · Director · CEO & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,500 Underlying: Common Stock · 35,500 shares Expires 2033-09-15 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing September 30, 2023. Read SEC document |
| October 01, 2008 Filed Oct 2, 2008 15:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 4,253 | $0.00 Strike: $13.63 | $0.00 |
DisclosureSEC source: 0000875320-08-000076 · edgar.xml · derivative · entry 4 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,761 Underlying: Common Stock · 4,253 shares Expires 2008-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| October 01, 2008 Filed Oct 2, 2008 15:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,253 | $32.65 | $138,860.45 |
DisclosureSEC source: 0000875320-08-000076 · edgar.xml · nonDerivative · entry 2 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,792 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $32.65 (range $32.30 to $33.08). F3 · price: Dr. Alam undertakes to provide (upon request by the SEC staff, the issuer or security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2008 Filed Oct 2, 2008 15:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,253 | $13.63 | $57,968.39 |
DisclosureSEC source: 0000875320-08-000076 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2008 Filed Sep 11, 2008 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 6,614 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0000875320-08-000072 · edgar.xml · derivative · entry 4 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,614 shares Expires 2008-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| September 10, 2008 Filed Sep 11, 2008 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,614 | $26.23 | $173,485.22 |
DisclosureSEC source: 0000875320-08-000072 · edgar.xml · nonDerivative · entry 2 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,792 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $26.34 (range $26.02 to $26.42). F3 · price: Dr. Alam undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| September 10, 2008 Filed Sep 11, 2008 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,614 | $10.19 | $67,396.66 |
DisclosureSEC source: 0000875320-08-000072 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2008 Filed Sep 4, 2008 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 6,612 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0000875320-08-000071 · edgar.xml · derivative · entry 4 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,614 Underlying: Common Stock · 6,612 shares Expires 2008-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| September 03, 2008 Filed Sep 4, 2008 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,612 | $25.86 | $170,986.32 |
DisclosureSEC source: 0000875320-08-000071 · edgar.xml · nonDerivative · entry 2 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,792 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $25.86 (range $25.49 to $26.26). F3 · price: Dr. Alam undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| September 03, 2008 Filed Sep 4, 2008 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,612 | $10.19 | $67,376.28 |
DisclosureSEC source: 0000875320-08-000071 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2008 Filed Aug 28, 2008 17:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 6,612 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0000875320-08-000069 · edgar.xml · derivative · entry 4 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,226 Underlying: Common Stock · 6,612 shares Expires 2008-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| August 27, 2008 Filed Aug 28, 2008 17:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,612 | $27.02 | $178,656.24 |
DisclosureSEC source: 0000875320-08-000069 · edgar.xml · nonDerivative · entry 2 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,792 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $27.02 (range $26.70 to $27.47). F3 · price: Dr. Alam undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 27, 2008 Filed Aug 28, 2008 17:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,612 | $10.19 | $67,376.28 |
DisclosureSEC source: 0000875320-08-000069 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2008 Filed Aug 21, 2008 17:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 6,612 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0000875320-08-000066 · edgar.xml · derivative · entry 5 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,838 Underlying: Common Stock · 6,612 shares Expires 2008-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| August 20, 2008 Filed Aug 21, 2008 17:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,920 | $27.99 | $53,740.80 |
DisclosureSEC source: 0000875320-08-000066 · edgar.xml · nonDerivative · entry 3 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,792 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. F3 · price: Open market sales reported on thsi line occurred at a weighted average price of $27.99 (range $27.91 to $28.10). F4 · price: Dr. Alam undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 20, 2008 Filed Aug 21, 2008 17:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,692 | $27.40 | $128,560.80 |
DisclosureSEC source: 0000875320-08-000066 · edgar.xml · nonDerivative · entry 2 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,712 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $27.40 (range $26.96 to $27.78). F4 · price: Dr. Alam undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 20, 2008 Filed Aug 21, 2008 17:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,612 | $10.19 | $67,376.28 |
DisclosureSEC source: 0000875320-08-000066 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2008 Filed Jul 25, 2008 14:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Options · Derivative | 36,250 | $0.00 Strike: $32.16 | $0.00 |
DisclosureSEC source: 0000875320-08-000052 · edgar.xml · derivative · entry 1 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,250 Underlying: Common Stock · 36,250 shares Expires 2018-07-23 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/24/2008. Read SEC document |
| June 19, 2008 Filed Jun 23, 2008 15:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 3,459 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0000875320-08-000046 · edgar.xml · derivative · entry 5 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,459 shares Expires 2013-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 4 years. Read SEC document |
| June 19, 2008 Filed Jun 23, 2008 15:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 4,822 | $0.00 Strike: $15.87 | $0.00 |
DisclosureSEC source: 0000875320-08-000046 · edgar.xml · derivative · entry 4 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,822 shares Expires 2012-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 4 years. Read SEC document |
| June 19, 2008 Filed Jun 23, 2008 15:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,459 | $15.60 | $53,960.40 |
DisclosureSEC source: 0000875320-08-000046 · edgar.xml · nonDerivative · entry 2 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2008 Filed Jun 23, 2008 15:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,822 | $15.87 | $76,525.14 |
DisclosureSEC source: 0000875320-08-000046 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2008 Filed May 22, 2008 13:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 80 | $27.89 | $2,231.20 |
DisclosureSEC source: 0000875320-08-000029 · edgar.xml · nonDerivative · entry 8 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,511 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 22, 2008 13:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 80 | $27.65 | $2,212.00 |
DisclosureSEC source: 0000875320-08-000029 · edgar.xml · nonDerivative · entry 7 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,591 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 22, 2008 13:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 81 | $27.64 | $2,238.84 |
DisclosureSEC source: 0000875320-08-000029 · edgar.xml · nonDerivative · entry 6 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,671 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 22, 2008 13:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 80 | $27.54 | $2,203.20 |
DisclosureSEC source: 0000875320-08-000029 · edgar.xml · nonDerivative · entry 5 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,752 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 22, 2008 13:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 80 | $27.71 | $2,216.80 |
DisclosureSEC source: 0000875320-08-000029 · edgar.xml · nonDerivative · entry 4 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,832 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 22, 2008 13:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 160 | $27.61 | $4,417.60 |
DisclosureSEC source: 0000875320-08-000029 · edgar.xml · nonDerivative · entry 3 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,912 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 22, 2008 13:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 80 | $27.59 | $2,207.20 |
DisclosureSEC source: 0000875320-08-000029 · edgar.xml · nonDerivative · entry 2 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,072 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 22, 2008 13:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 161 | $27.47 | $4,422.67 |
DisclosureSEC source: 0000875320-08-000029 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,152 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
| February 07, 2008 Filed Feb 11, 2008 20:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 36,250 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0000875320-08-000003 · edgar.xml · derivative · entry 3 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,250 Underlying: Common Stock · 36,250 shares Expires 2018-02-06 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/07/2008, subject to shareholder approval. Read SEC document |
| February 07, 2008 Filed Feb 11, 2008 20:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 9,667 | $0.01 | $96.67 |
DisclosureSEC source: 0000875320-08-000003 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,511 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/7/2012, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| December 11, 2007 Filed Dec 12, 2007 16:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 45 | $25.96 | $1,168.20 |
DisclosureSEC source: 0000875320-07-000121 · edgar.xml · nonDerivative · entry 8 ALAM JOHN J · CIK 0001197014 · EVP, Medicines Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,844 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
| December 11, 2007 Filed Dec 12, 2007 16:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 50 | $25.82 | $1,291.00 |
DisclosureSEC source: 0000875320-07-000121 · edgar.xml · nonDerivative · entry 7 ALAM JOHN J · CIK 0001197014 · EVP, Medicines Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,889 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
| December 11, 2007 Filed Dec 12, 2007 16:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 45 | $25.60 | $1,152.00 |
DisclosureSEC source: 0000875320-07-000121 · edgar.xml · nonDerivative · entry 6 ALAM JOHN J · CIK 0001197014 · EVP, Medicines Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,939 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
| December 11, 2007 Filed Dec 12, 2007 16:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 140 | $25.59 | $3,582.60 |
DisclosureSEC source: 0000875320-07-000121 · edgar.xml · nonDerivative · entry 5 ALAM JOHN J · CIK 0001197014 · EVP, Medicines Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,984 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.